Last updated: 7 June 2024 at 5:33pm EST

Owen Witte Net Worth




The estimated Net Worth of Owen N. Witte is at least $7.36 Millón dollars as of 11 August 2022. Owen Witte owns over 15,000 units of Allogene Therapeutics Inc stock worth over $635,169 and over the last 8 years he sold ALLO stock worth over $6,247,223. In addition, he makes $474,988 as Independent Director at Allogene Therapeutics Inc.

Owen Witte ALLO stock SEC Form 4 insiders trading

Owen has made over 9 trades of the Allogene Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of ALLO stock worth $251,250 on 11 August 2022.

The largest trade he's ever made was selling 25,000 units of Allogene Therapeutics Inc stock on 23 June 2017 worth over $2,507,500. On average, Owen trades about 6,840 units every 99 days since 2017. As of 11 August 2022 he still owns at least 218,271 units of Allogene Therapeutics Inc stock.

You can see the complete history of Owen Witte stock trades at the bottom of the page.





Owen Witte biography

Dr. Owen N. Witte, M.D. serves as Independent Director of the Company. Dr. Witte previously served as a member of the board of directors of Kite Pharma, Inc. (“Kite”) from March 2017 until October 2017. Dr. Witte joined the UCLA faculty in 1980, where he is presently a University Professor of microbiology, immunology and molecular genetics, the UCLA David Saxon Presidential Chair in Developmental Immunology and the director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Dr. Witte was appointed a University Professor by the University of California Board of Regents, an honor reserved for scholars of the highest international distinction. Dr. Witte is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. Dr. Witte currently serves on several editorial and advisory boards. He previously served on the board of directors for the American Association for Cancer Research. He was appointed by President Obama to the President’s Cancer Panel. Dr. Witte holds a bachelor’s degree from Cornell University and an M.D. from Stanford University. He completed postdoctoral research at the Massachusetts Institute of Technology.

What is the salary of Owen Witte?

As the Independent Director of Allogene Therapeutics Inc, the total compensation of Owen Witte at Allogene Therapeutics Inc is $474,988. There are 16 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.



How old is Owen Witte?

Owen Witte is 70, he's been the Independent Director of Allogene Therapeutics Inc since 2018. There are 4 older and 16 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.

Insiders trading at Allogene Therapeutics Inc

Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun y Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.



What does Allogene Therapeutics Inc do?

allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le



What does Allogene Therapeutics Inc's logo look like?

Allogene Therapeutics Inc logo

Complete history of Owen Witte stock trades at Allogene Therapeutics Inc

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
11 Aug 2022 Owen N. Witte
Venta 15,000 $16.75 $251,250
11 Aug 2022
218,271
11 Aug 2022 Owen N. Witte
Venta 15,000 $16.75 $251,250
11 Aug 2022
218,271
22 Jun 2022 Owen N. Witte
Venta 10,000 $11.76 $117,600
22 Jun 2022
233,271
9 Sep 2021 Owen N. Witte
Venta 5,000 $25.54 $127,700
9 Sep 2021
221,182
20 Aug 2021 Owen N. Witte
Venta 10,000 $23.47 $234,700
20 Aug 2021
226,182
9 Jun 2021 Owen N. Witte
Venta 9,969 $25.05 $249,723
9 Jun 2021
236,182
15 Oct 2018 Owen N. Witte
Comprar 15,000 $18.00 $270,000
15 Oct 2018
198,750


Allogene Therapeutics Inc executives and stock owners

Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: